Company news

Creative Medical Technology Holdings, Inc. news in 2023

Creative Medical Technology Holdings, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Creative Medical Technology Holdings (NASDAQ: CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

December 19, 2023

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

October 9, 2023

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

September 18, 2023

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

June 27, 2023

Creative Medical Technology Announces $2 Million Share Repurchase Program

June 11, 2023

Creative Medical Technology Holdings Announces Reverse Stock Split

June 8, 2023

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform

May 30, 2023

Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

May 21, 2023

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

May 17, 2023

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

April 11, 2023

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

April 3, 2023

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes

March 22, 2023

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development

March 20, 2023

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

March 6, 2023

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

February 7, 2023